Company Overview and News

3
Boston Properties Announces 18.75% Sequential Dividend Hike

2018-09-19 zacks
Boston Properties, Inc. (BXP - Free Report) , on Sep 18, announced rewards for shareholders in the form of a 18.75% sequential hike in the quarterly dividend rate. In fact, the new dividend of 95 cents, way above the previously-announced dividends of 80 cents, indicates a hike of more than 46% over the past three years.
UNP BXP WPC VICI

 
Boston Properties boosts dividend by 19%, the biggest increase in its history

2018-09-18 marketwatch
Boston Properties Inc. BXP, +0.83% said Tuesday it will raise its quarterly dividend by 19% to 95 cents a share from 80 cents a share, which the real estate investment trust said was the biggest quarterly increase in its history. The new dividend will be payable Oct. 31 to shareholders of record on Sept. 28. Based on Monday's stock closing price of $127.01, the new annual dividend rate implies a yield of 2.
BXP

 
BXP / Boston Properties, Inc. null

2018-09-17 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8F)D [email protected]&)@8%H*(ADKP60*B&2. I,Z8%E-,/D-3(J#20
BXP

 
BXP / Boston Properties, Inc. null

2018-09-17 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8F)D [email protected]&)@8%H*(ADKP60*B&2. I,Z8%E-,/D-3(J#20
BXP

 
BXP / Boston Properties, Inc. null

2018-09-17 sec.gov
Document Ms. Jennifer Monick Assistant Chief A
BXP

 
BXP / Boston Properties, Inc. null

2018-09-17 sec.gov
Document Ms. Jennifer Monick Assistant Chief A
BXP

 
BXP / Boston Properties, Inc. null

2018-09-17 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0X(# @;V)J#3P\+TQI;F5A
BXP

 
BXP / Boston Properties, Inc. null

2018-09-17 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0X(# @;V)J#3P\+TQI;F5A
BXP

 
Lamar Advertising started at outperform with $93 stock price target at Imperial Capital

2018-09-13 marketwatch
A tight labor market and changing job requirements are pushing companies to invest in teaching current workers to do more sophisticated tasks. Two-thirds of manufacturers plan to increase training in the next year, according to a report.
REG BXP OPRF PSA.A EXR PSAXZ O PSA

 
Best High-Yield REIT CEF - For Growth And Income - 7.6% Yield

2018-09-08 seekingalpha
After trading flat for almost three years, REITs are cheap with relatively low FFO multiples, discounts to NAV, and high dividend yields.
HTA BXP PSA.A RQI PSAXZ VTR EQIX PSA CNS PLD

4
REITs Are A Natural Hedge Against Trade Risk

2018-09-07 seekingalpha
But, if it were to escalate to a 'trade war', we believe commercial real estate would outperform traditional equities.
DRE CAT VNO.WI VNORP BXP AMT COR STAG VNO LXP FR PLD WPC REXR LPT BA SLG

 
Boston Properties (BXP) Up 0.6% Since Last Earnings Report: Can It Continue?

2018-08-30 zacks
It has been about a month since the last earnings report for Boston Properties (BXP - Free Report) . Shares have added about 0.6% in that time frame, underperforming the S&P 500.
BXP

 
IPG (IPGP) Up 3.4% Since Last Earnings Report: Can It Continue?

2018-08-30 zacks
It has been about a month since the last earnings report for IPG Photonics (IPGP - Free Report) . Shares have added about 3.4% in that time frame, underperforming the S&P 500.
IPGP BXP

 
C.H. Robinson (CHRW) Up 0.7% Since Last Earnings Report: Can It Continue?

2018-08-30 zacks
It has been about a month since the last earnings report for C.H. Robinson Worldwide (CHRW - Free Report) . Shares have added about 0.7% in that time frame, underperforming the S&P 500.
BXP CHRW

 
CommScope (COMM) Down 0.1% Since Last Earnings Report: Can It Rebound?

2018-08-30 zacks
It has been about a month since the last earnings report for CommScope (COMM - Free Report) . Shares have lost about 0.1% in that time frame, underperforming the S&P 500.
BXP

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 101121101